arrow
B

Brandon Cieniewicz

cero therapeutics holdings inc
H指数:10
被引数:1,248

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-In-Human Clinical Experience with CER-1236, a First-In-Class TIM-4–Based Phagocytic CAR-T Therapy, Including Platelet Transfusion Independence In an Index Patient with High-Risk MDS/AML (inv(3)/Mecom)

首次人体临床试验经验:CER-1236,一种首创的基于TIM-4的吞噬性CAR-T疗法,包括在一名高风险MDS/AML(inv(3)/Mecom)索引患者中的血小板输注独立性。

2026-03-100
PRE
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation
2023-07-014
OAAI
Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients
2021-10-2738
OA
Identification of preexisting adaptive immunity to Cas9 proteins in humans
2019-01-28663
OAAI